Eli Lilly and Company
CD226 AGONIST ANTIBODIES
Last updated:
Abstract:
The present invention relates to anti-human CD226 agonist antibodies, which can be useful for treating solid tumor cancers.
Status:
Application
Type:
Utility
Filling date:
19 Jul 2019
Issue date:
25 Nov 2021